Form 4: Calidi Biotherapeutics Director George Peoples Receives Stock Option Grant

Calidi Biotherapeutics, Inc. Director George Peoples was granted non-qualified stock options to purchase 137,078 shares of common stock at an exercise price of $0.70 per share.

Summary

• Director George Peoples was issued non-qualified stock options to purchase 137,078 shares of Calidi Biotherapeutics, Inc. common stock.
• The exercise price for these options is $0.70 per share, which was equal to the closing price on the grant date.
• The options were granted on July 9, 2025, and issued on July 15, 2025.
• Vesting will occur in 1/12th per month installments over one year, commencing on the grant date of July 9, 2025.
• The options expire on July 9, 2035.
• This grant was made pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns interests without indicating any immediate operational changes or financial distress.

Positives

• The grant of stock options aligns the interests of Director George Peoples with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of a pre-existing, established compensation policy for non-employee directors, indicating structured corporate governance.

Future Outlook

The document details a standard compensation event for a non-employee director, reflecting the ongoing implementation of the company's equity incentive plan. It does not provide specific forward-looking statements regarding the company's operational or financial performance.

Management Comments

• The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

Industry Context

The granting of stock options to non-employee directors is a common practice across publicly traded companies, particularly in the biotechnology sector, to attract and retain qualified board members and align their interests with long-term shareholder value. This transaction is consistent with standard corporate governance and compensation practices within the industry.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism across the biotechnology and broader public company landscape, aiming to align director incentives with shareholder returns.
• The vesting schedule of 1/12th per month over one year is a common approach for director equity grants, promoting continued service and long-term commitment.
• The exercise price being equal to the closing price on the grant date is typical for non-qualified stock options issued as part of compensation plans.

Corporate Governance

Related Party Transactions

• The grant of non-qualified stock options to George Peoples, a director of Calidi Biotherapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's management.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised in the future, but also benefit from increased alignment of director incentives with long-term company performance.
• Director George Peoples: Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The granted options will vest in 1/12th per month installments over one year, commencing on July 9, 2025, making them exercisable as they vest.

Key Dates

Keywords

Calidi Biotherapeutics, CLDI, Stock Options, Director Compensation, Equity Incentive Plan, SEC Form 4, Beneficial Ownership, Insider Transaction